key articles
Circulating tumor cells for predicting androgen deprivation response of hormone naive metastatic prostate cancer
Wednesday, 17 September 2008 - Okegawa et al. (2008) determined whether circulating tumor cells predict prostate specific antigen failure in patients with metastatic prostate cancer before endocrine therapy and compared their...
Authors: Okegawa et al.
Does prostate growth confound prostate specific antigen velocity?
Tuesday, 16 September 2008 - Although prostate specific antigen velocity was proposed to increase the specificity of prostate specific antigen-based screening, there are little published data on the effect of differential...
Authors: Loeb et al.
Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy
Tuesday, 16 September 2008 - Studies on time needed for testosterone recovery in patients who have undergone androgen deprivation therapy, usually measure androgen every 3 months. Gulley et al. (2008) reported the largest study...
Authors: Gulley et al.
Outcomes of active surveillance of localized prostate cancer patients diagnosed in the prostate specific antigen era
Monday, 15 September 2008 - Ercole et al. (2008) reported outcomes associated with men who choose active surveillance for the management of localized prostate cancer.
This is a retrospective case series analysis of 40 patients...
Authors: Ercole et al.
Racial variations in levels of prostate specific antigen and its density
Monday, 15 September 2008 - The incidence of prostate cancer is known to vary as a function of race. To date few studies have evaluated the performance of the prostate specific antigen test and its indexes in unique racial...
Authors: Elliott et al.
Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy
Sunday, 14 September 2008 - For patients with prostate cancer treated by radical prostatectomy, no current personalized tools predict clinical failure (CF; metastasis and/or androgen-independent disease). Donovan et al. (2008)...
Authors: Donovan et al.
Phase III trial of neoadjuvant androgen deprivation for clinically localized prostate cancer
Friday, 12 September 2008 - Crook et al. (2008) evaluated the effect of 3 versus 8 months of neoadjuvant hormonal therapy before conventional-dose radiotherapy (RT) on disease-free survival for localized prostate cancer.
Between...
Authors: Crook et al.
Assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for prostate cancer patients
Friday, 12 September 2008 - Pearse et al. (2008) assessed the acute and late gastrointestinal (GI) and genitourinary (GU) toxicity of salvage radiotherapy (RT).
A total of 75 patients with prostate-specific antigen relapse or...
Authors: Pearse et al.
Obesity and risk of biochemical failure for patients receiving salvage radiotherapy after prostatectomy
Friday, 12 September 2008 - Obesity has been proposed as an independent risk factor for patients undergoing surgery or radiotherapy (RT) for prostate cancer. Using body mass index (BMI) as a measure of obesity, King et al. (2008)...
Authors: King et al.
How many patients with newly diagnosed prostate cancer are candidates for surveillance?
Thursday, 11 September 2008 - Active surveillance is an option for men with clinically localized prostate cancer and may be suitable for those with very low risk disease. Barocas et al. (2008) determined the percentage of men in...
Authors: Barocas et al.
